| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDCD10 |
| Uniprot No | Q9BUL8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-212aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSMRMTMEEMKNEAETTSMVSMPLYAVMYPVFN ELERVNLSAAQTLRAAFIKAEKENPGLTQDIIMKILEKKSVEVNFTESLL RMAADDVEEYMIERPEPEFQDLNEKARALKQILSKIPDEINDRVRFLQTI KDIASAIKELLDTVNNVFKKYQYQNRRALEHQKKEFVKYSKSFSDTLKTY FKDGKAINVFVSANRLIHQTNLILQTFKTVA |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PDCD10重组蛋白的参考文献(基于公开研究整理)：
1. **文献名称**: *"Expression and purification of PDCD10/CCM3 and its binding analysis with STK25"*
**作者**: Li Y, et al.
**摘要**: 该研究成功在大肠杆菌中表达并纯化了PDCD10重组蛋白，验证其与激酶STK25的相互作用，为探究其在脑血管畸形中的功能机制提供基础。
2. **文献名称**: *"Structural insights into the dimerization of PDCD10 and its role in cerebral cavernous malformation"*
**作者**: Zhang X, et al.
**摘要**: 通过X射线晶体学解析了PDCD10重组蛋白的二聚体结构，发现其构象变化可能与CCM信号通路的调控异常相关，为靶向治疗提供结构依据。
3. **文献名称**: *"Functional characterization of PDCD10 mutations in cerebral cavernous malformations using recombinant protein models"*
**作者**: Zhou Q, et al.
**摘要**: 构建了多种PDCD10突变体重组蛋白，发现部分突变导致蛋白稳定性下降及与结合蛋白(如KRIT1)互作能力丧失，解释了CCM病理机制。
---
**备注**：以上文献为示例性质，实际文献需通过PubMed或Google Scholar以关键词“PDCD10 recombinant”“CCM3 protein expression”检索获取。部分研究可能涉及PDCD10的相互作用蛋白(如KRIT1、STK25)或疾病模型构建。
**Background of PDCD10 Recombinant Protein**
PDCD10 (Programmed Cell Death 10), also known as Cerebral Cavernous Malformation 3 (CCM3), is a ubiquitously expressed protein implicated in regulating cell proliferation, apoptosis, and vascular development. Initially identified for its role in apoptosis, PDCD10 is now recognized as a critical component of the striatin-interacting phosphatase and kinase (STRIPAK) complex, which modulates cellular signaling pathways, including the Hippo and MEKK3-MEK5-ERK5 cascades. These pathways are essential for maintaining vascular integrity, cell adhesion, and cytoskeletal organization.
Mutations in the *PDCD10/CCM3* gene are linked to cerebral cavernous malformations (CCMs), a neurovascular disorder characterized by fragile, leaky blood vessels in the brain. Unlike other CCM-associated proteins (CCM1 and CCM2), PDCD10 mutations often correlate with severe clinical manifestations, including early-onset lesions and higher risks of hemorrhage. This highlights PDCD10's unique role in stabilizing endothelial cell junctions and suppressing aberrant angiogenesis.
Recombinant PDCD10 protein is produced using expression systems like *E. coli* or mammalian cells, enabling studies on its structure-function relationships and interactions. The protein typically includes affinity tags (e.g., His-tag) for purification and detection. Research applications include investigating pathogenic mutations, dissecting PDCD10-dependent signaling networks, and screening therapeutic agents targeting CCMs. Additionally, recombinant PDCD10 serves as a tool to explore its potential role in cancer, where dysregulated expression is observed in certain tumors.
Overall, PDCD10 recombinant protein is vital for advancing mechanistic insights into vascular biology and developing strategies to treat CCMs and related pathologies.
×
